NRC NRC HEALTH
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 70487 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.4%
TTM net income YoY-60.6%
TTM EPS YoY6,909.9%
Revenue 3-yr CAGR-1.1%
Net income 3-yr CAGR-39.3%
Margins
Gross margin—
Operating margin11.1%
Net margin4.5%
FCF margin12.8%
EBITDA margin17.0%
Returns
ROE248.1%
ROA4.7%
ROIC (approx.)10.9%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets106.6%
Debt / equity—
Current ratio0.64x
Interest coverage2.91x
Cash quality & payout
Operating cash flow / net income3.69x
Accruals ratio-12.6%
Payout ratio209.2%
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $137.39M | $143.06M |
| SG&A expense | $54.80M | $44.91M |
| Operating income | $22.59M | $35.19M |
| Interest expense | $4.76M | $2.60M |
| Pretax income | $17.84M | $32.69M |
| Income tax | $6.25M | $7.91M |
| Net income | $11.60M | $24.78M |
| EBITDA | $30.21M | $41.22M |
| EPS (basic) | 50.00 | 1.05 |
| EPS (diluted) | 50.00 | 1.04 |
| Dividends declared per share | 0.52 | 0.48 |
| Weighted avg. shares (diluted) | 22.40M | 23.74M |
| Balance sheet | ||
| Cash & equivalents | $4.14M | $4.23M |
| Receivables | $11.11M | $11.05M |
| Current assets | $20.21M | $19.60M |
| PP&E, net | $40.47M | $38.27M |
| Goodwill | $66.15M | $66.15M |
| Intangibles | $2.23M | $2.62M |
| Total assets | $134.88M | $132.54M |
| Current liabilities | $36.62M | $35.86M |
| Short-term debt | $4.01M | — |
| Long-term debt | $75.02M | $57.90M |
| Total debt | $79.03M | $57.90M |
| Total liabilities | $120.89M | $101.25M |
| Shareholders' equity | $13.99M | $31.28M |
| Net debt | $74.90M | $53.66M |
| Shares outstanding | 22.64M | 23.08M |
| Cash flow statement | ||
| Operating cash flow | $26.45M | $34.62M |
| Capital expenditure | $10.71M | $15.45M |
| Free cash flow | $15.74M | $19.18M |
| Investing cash flow | -$10.71M | -$20.28M |
| Financing cash flow | -$15.84M | -$16.76M |
| Depreciation & amortization | $7.62M | $6.02M |
| Stock-based compensation | $3.31M | $284,000 |
| Dividends paid | $10.98M | $11.45M |
| Share buybacks | $20.18M | $30.95M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.